We are very excited to announce a major research collaboration and option to license agreement with Chugai Pharmaceutical! ararisbiotech.com/docs/250106_25… #Araris #ADCs

Fantastic news from our portfolio company, Araris Biotech , as they announce a research collaboration with Chugai Pharmaceutical! #4BIO #Araris #ADCs #VC #AdvancedTherapies #Collaboration

Please give a warm welcome to Jack Shea-Firth who joins 4BIO as an Investment Analyst! We look forward to working with you, Jack! #4BIO #NewHire #AdvancedTherapies

Addressing patient access & pricing in cell & gene therapy: Tay Salimullah moderated an insightful #PMWC2024 discussion with James M. Wilson & Courtney Silverthorn. 4BIO Capital is investing in companies breaking these barriers. #CellAndGeneTherapy

On Wednesday the 5th of March, Principal, Natalie Johnston will be attending the RNA Leaders Europe Congress in Basel, Switzerland. Natalie will be taking part in the Next Generation RNA: Rapid Fire Session at 13:50 CET. #RNAtherapeutics #RNA #4BIO #RNAleaders

We are proud to share the news that our portfolio company, Araris Biotech has entered into an agreement to be acquired by Taiho Pharmaceutical. Read the press release: 4biocapital.com/single-post/ar… #4BIO #Araris #ADCs #VC #AdvancedTherapies #Acquisition

Last week, Owen Smith, Partner participated as a panellist at ARM’s Cell & Gene Meeting on the Med in Rome. He joined fellow industry leaders for the panel titled "Investing in the ATMP Sector: Trends, Opportunities, and Risks." #4BIOCapital #CGMed25 #MeetingOnTheMed

Next week, Venture Partner, Tay Salimullah will be joining a panel at the BioCentury Grand Rounds U.S. in Chicago on 5 June! They’ll be diving into “Modalities face-off: what will prevail, and is there room to share?” #4BIO #VC #AdvancedTherapies

Owen Smith, Partner, sat down with Giovanni Amodeo at Mergermarket to discuss 4BIO and our investment strategy. Listen to the full interview here: ionanalytics.com/insights/merge… #4BIO #VC #AdvancedTherapies #Interview

Kieran Mudryy, Partner, spoke on the keynote panel and Q&A: Charting Recent Investment Trends and Deal Flow into Today’s Healthcare Industry at this year’s BeyondActiv Beyond Health event in Singapore. #4BIO #VC #AdvancedTherapies #Panel #Networking

4BIO Capital co-leads Actithera's $75.5M Series A to advance precision radiopharmaceutical therapies. 4biocapital.com/single-post/4b… #4BIO #VC #AdvancedTherapies #Radiopharmaceuticals #Investment #Fundraise

We’re thrilled to have been shortlisted as a finalist in the ‘Venture Capital Firm of the Year’ category at the European Lifestars Awards alongside other industry leaders. Good luck to all the other finalists! #LifestarsAwards #4BIO #Awards #VC

Natalie Johnston, Principal at 4BIO, will be at an HSBC Innovation Banking Oncology Innovation Day on Thursday, taking part on the ‘Current Funding Landscape’ panel. This exclusive event brings together leading VCs, pharma executives and oncology founders. #HSBCInnovationDay

We are proud to share the news that our portfolio company, Trogenix, has announced a £70 million Series A financing round. Read the press release: 4biocapital.com/single-post/4b… #4BIO #Trogenix #Biotech #Financing #VC

Thank you to the HSBC Innovation Banking team who hosted their Oncology Innovation Day in London where Natalie Johnston, Principal at 4BIO, was there to speak on a panel. #HSBCInnovationDay #4BIO

Our Managing Partner Dima Kuzmin featured in Scrip, Citeline Commercial's 2026 outlook: "Technical validation could become the primary driver of capital allocation in 2026." Companies with clear execution pathways—not just elegant biology—will win. insights.citeline.com/scrip/scrip-as… #VC #2026Outlook

𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: Dima Kuzmin, founder and co-managing partner of venture firm 4BIO Capital, is optimistic for the coming year, but says that investors must increase support for platform companies.

A thoughtful piece in the Financial Times featuring Dima Kuzmin in conversation with Aanu Adeoye on the structural challenges facing UK and European biotech, and what’s needed to help ambitious companies scale at home. Read more here: ft.com/content/0fbb73… #4BIO #VC #FT

We’re pleased to announce that Thera Liechtenstein has been promoted to Partner and Tetsu Maruyama joins as Venture Partner. Congratulations Thera and welcome Tetsu! Read more here: 4biocapital.com/single-post/4b… #4BIO #Appointments #NewHire #VC #Biotech

Pleased to share that our portfolio company Trogenix has published breakthrough pre‑clinical data in Nature, showing complete tumour eradication and durable protection in an aggressive glioblastoma model. nature.com/articles/s4158… #4BIO #VC #Portfolio